C0086661||MYC
C0808232||therapeutic intervention
C0238461||anaplastic thyroid cancer
C2603343||Recent studies
C0040649||transcription
C0086661||MYC gene
C0033684||bromodomain and extraterminal domain (BET) proteins
C2753333||acetylated histones
C0008546||chromatin
C1254351||potent inhibitor
C3252362||JQ1
C0033684||BET proteins
C2753333||acetylated histones
C0040649||transcription
C0086661||MYC gene
C0700287||recently reported
C3252362||JQ1
C0040136||thyroid tumor
C0184511||improved
C2986594||mouse model
C0238461||anaplastic thyroid cancer
C0238461||anaplastic thyroid cancer
C0086661||MYC
C0040649||transcription
C1454487||MYC in human
C0238461||anaplastic thyroid cancer
C1454487||MYC
C0009429||novel treatment modality
C3537153||molecular mechanisms
C0086418||human
C0238461||anaplastic thyroid cancer
C0220825||evaluated
C0086418||human
C0238461||anaplastic thyroid cancer
C0085983||cell lines
C1520166||xenograft models
C1269955||invasion
C0085983||cell lines
C0520484||xenograft
C0027651||tumors
C1269955||invasion of tumor cells
C0238461||anaplastic thyroid cancer
C0085983||cell lines
C1454487||MYC
C0702240||elevation
C0598086||p21and p27
C1158886||phosphorylated
C0080113||Rb
C0007586||delay cell cycle
C1269955||cell invasion
C1523298||epithelial mesenchymal transition signals
C2603343||cell-based studies
C0750484||confirmed
C0520484||xenograft
C2603343||studies
C0456389||size
C0037080||p21-Cyclin/CDK-Rb-E2F signaling
C1454487||MYC protein
C0009429||novel treatment modality
C0086418||human
C0238461||anaplastic thyroid cancer
C0683525||treatment options